The values of OssiFi Therapeutics are an integral part of how we operate.Our research & development is only successful if we improve patient quality of life
by producing the best-in-classproducts.
Corporate Development
Privately held company. Since its inception, it has been capitalized using convertible notes, non-dilutive grants, and equity.
OssiFi is developing best in class sclerostin small molecule inhibitors to take advantage of new opportunities to develop safer, more effective bone building therapies.
OssiFi Therapeutics is an innovative bone-biology company operating at the intersection of therapeutics and medical devices to address significant unmet needs in neurogenic low back pain, fracture repair, and fracture prevention.